AOD-9604 Patient Assistance for Low-Income: How to Reduce Cost in 2026

What AOD-9604 Is and Why Access Is Complicated

AOD-9604 is a synthetic peptide corresponding to amino acids 176 through 191 of human growth hormone, with an added tyrosine residue at the N-terminus. Early research suggested it could stimulate lipolysis without the diabetogenic or growth-promoting effects of full-length HGH [1]. That distinction matters for cost and access: because AOD-9604 never completed the FDA approval pathway, it exists in a regulatory gray zone that eliminates most traditional cost-reduction tools available to patients.

No branded product means no manufacturer. No manufacturer means no copay card, no patient assistance program (PAP), and no pathway onto commercial insurance formularies. The peptide is available exclusively through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [2]. This legal framework permits pharmacies to compound AOD-9604 using bulk pharmaceutical-grade ingredients, but it also means pricing is set pharmacy by pharmacy with no standardized retail benchmark. Patients prescribed AOD-9604 by a licensed provider are paying entirely out of pocket in virtually every case. The FDA's 2024 and 2025 updates to its bulk drug substance nominations list directly affect which peptides compounding pharmacies can legally prepare, so availability itself can shift on relatively short notice [3].

Average Cost of AOD-9604 in 2026

A typical 30-day supply of compounded AOD-9604 costs between $120 and $250, though that range depends on three variables: concentration per vial, total monthly dose, and the specific compounding pharmacy filling the prescription.

Most compounding pharmacies dispense AOD-9604 as a lyophilized powder for reconstitution, sold in vials containing 5 mg or 10 mg of peptide. At a standard dose of 300 mcg per day, a 5 mg vial lasts roughly 16 days. Patients dosing at 500 mcg daily will go through a 5 mg vial in 10 days. The per-vial price typically falls between $60 and $130 at 503A pharmacies, with 503B outsourcing facilities sometimes charging less per unit due to batch manufacturing efficiencies [2]. Shipping adds $10 to $25 per order depending on cold-chain requirements, since reconstituted AOD-9604 requires refrigeration at 2 to 8 degrees Celsius.

Telehealth platforms that bundle the provider consultation with peptide dispensing tend to land between $150 and $199 per month all-in. That price includes the prescriber visit, the compounded vial, and shipping. For patients who would otherwise pay separately for a consultation ($75 to $150) and a vial ($60 to $130), the bundled model can represent a 15% to 30% savings on total monthly spend. Comparing three to four pharmacy quotes before filling is the single most effective cost-reduction step, since price variation across compounding pharmacies routinely exceeds 40% for the same peptide at the same concentration [4].

Why There Is No Manufacturer Coupon or Traditional PAP

Patient assistance programs exist because brand-name pharmaceutical manufacturers fund them. Novo Nordisk runs a PAP for semaglutide. Eli Lilly runs one for tirzepatide. These programs require an FDA-approved product tied to a specific NDA or BLA holder [5]. AOD-9604 has neither.

The peptide was originally investigated by Metabolic Pharmaceuticals Limited, an Australian company that conducted Phase IIb trials in the early 2000s. A 2004 randomized controlled trial (N=300) evaluating oral AOD-9604 for obesity did not meet its primary endpoint of statistically significant weight loss versus placebo at 24 weeks [6]. Metabolic Pharmaceuticals did not advance the compound further. No other company has picked up development for an FDA submission. Without an NDA holder, no entity exists to fund a coupon program, a copay assistance card, or a PAP.

This is a permanent structural gap, not a temporary one. Unless a pharmaceutical company sponsors AOD-9604 through FDA approval, which would require new Phase III trials costing hundreds of millions of dollars, no manufacturer-backed financial assistance will materialize. Patients searching for "AOD-9604 manufacturer coupon" will find nothing legitimate.

Insurance Coverage: What the Data Shows

No major commercial health insurer, Medicare Part D plan, or Medicaid program covers AOD-9604. The reasons are straightforward. Insurance formularies list FDA-approved drugs [7]. AOD-9604 is not FDA-approved. Compounded medications occupy a narrow exception in some state Medicaid programs, but those exceptions typically apply to compounded versions of FDA-approved active ingredients (for example, a compounded suspension of an approved oral tablet for a patient who cannot swallow). AOD-9604 does not fit that exception because the base compound itself lacks approval.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) present a more nuanced picture. IRS rules permit HSA/FSA reimbursement for expenses that constitute "medical care" under Section 213(d) of the Internal Revenue Code [8]. A compounded peptide prescribed by a licensed physician for a diagnosed medical condition could qualify, though individual HSA/FSA administrators interpret this differently. Patients should request an itemized receipt from their compounding pharmacy and a letter of medical necessity from their prescriber before submitting claims.

Some patients with high-deductible health plans attempt to apply AOD-9604 costs toward their annual deductible. This rarely works. Most plans exclude compounded medications from deductible accumulation unless the plan document specifically includes them. Checking the plan's Summary of Benefits and Coverage (SBC) or calling the pharmacy benefits manager directly is the only reliable way to confirm.

Compounding Pharmacy Price Comparison Strategies

Because AOD-9604 pricing is unregulated and varies widely, systematic comparison shopping is the most practical cost-reduction tool. Three categories of compounding pharmacy serve the peptide market, and each carries different pricing dynamics.

503A pharmacies compound medications based on individual patient prescriptions. They are state-licensed and must comply with USP 797 and USP 800 sterile compounding standards [9]. Pricing at 503A pharmacies for a 5 mg vial of AOD-9604 ranges from $55 to $130. Patients located near multiple 503A pharmacies can request quotes from each. Many will price-match or offer multi-vial discounts when asked directly.

503B outsourcing facilities operate under federal FDA oversight and can compound without patient-specific prescriptions, producing larger batches. Their per-unit cost is often 10% to 25% lower than 503A pharmacies due to economies of scale [2]. The trade-off is that 503B facilities typically sell to clinics and prescribers rather than directly to patients, so patients access these prices through their provider's dispensing arrangement.

Telehealth-affiliated pharmacies partner with specific telehealth platforms. These pharmacies may offer lower peptide pricing in exchange for guaranteed prescription volume from the platform's prescribers. Patients using these platforms pay a single bundled price but sacrifice the ability to shop around for the pharmacy component independently.

A practical approach: request quotes from at least two 503A pharmacies and one telehealth bundle before filling. Ask each pharmacy for the cost per milligram rather than the cost per vial, since vial sizes and concentrations differ. A pharmacy charging $90 for a 5 mg vial ($18/mg) is cheaper per unit than one charging $110 for a 10 mg vial ($11/mg), but the 10 mg vial is the better deal if the patient will use the full contents before the 28-day beyond-use date.

State and Community Assistance Programs Worth Checking

While no program specifically targets AOD-9604, several broader assistance frameworks may reduce the financial burden for low-income patients using compounded medications.

State Pharmaceutical Assistance Programs (SPAPs) exist in 26 states and are designed to help residents who do not qualify for Medicaid but cannot afford their medications [10]. Most SPAPs focus on FDA-approved drugs, but a handful of states (including New York's EPIC program and Pennsylvania's PACE program) have provisions that can apply to compounded prescriptions when a physician documents medical necessity. Eligibility is income-based, typically set at 200% to 400% of the federal poverty level.

Federally Qualified Health Centers (FQHCs) serve patients on a sliding fee scale based on income. While FQHCs do not typically stock compounded peptides, their prescribers can write prescriptions for AOD-9604 that patients fill at external compounding pharmacies. The consultation visit itself is billed on the sliding scale, which can save $75 to $150 per visit compared to private telehealth platforms [11].

NeedyMeds and RxAssist databases catalog assistance programs across all medication types. Searching these databases for "compounded medications" or "peptide therapy" occasionally surfaces small nonprofit or foundation grants. The Alliance for Pharmacy Compounding (APC) also maintains a directory of member pharmacies, some of which offer hardship pricing for documented low-income patients [4].

Charitable care programs at academic medical centers sometimes cover compounded medications as part of research protocols or compassionate use arrangements. Patients near a university hospital with an endocrinology or obesity medicine department can ask whether any active protocols include AOD-9604 or related peptide fragments.

Telehealth Platforms and Bundled Pricing Models

The telehealth model has become the most common access pathway for AOD-9604 in 2026. These platforms pair an online prescriber consultation with direct-to-patient peptide dispensing from an affiliated compounding pharmacy. Monthly costs at major telehealth peptide platforms range from $149 to $250.

Several pricing structures exist. Some platforms charge a flat monthly subscription that includes the consultation, the peptide, supplies (syringes, alcohol swabs, sharps container), and shipping. Others separate the consultation fee (typically $50 to $99 per visit, billed monthly or quarterly) from the medication cost. For AOD-9604 specifically, the medication-only component at telehealth-affiliated pharmacies tends to run $80 to $150 per month.

"Patients should read the fine print on auto-renewal and cancellation policies," notes the American Telemedicine Association's 2025 consumer guidance on direct-to-patient prescribing platforms [12]. Some platforms lock patients into three- or six-month commitments with early cancellation fees, effectively raising the per-month cost if a patient discontinues before the commitment period ends.

Low-income patients evaluating telehealth options should ask three questions before signing up: (1) Can I pause my subscription without penalty if I cannot afford a given month? (2) Is the pharmacy 503A or 503B, and can I verify its state license or FDA registration number? (3) Does the platform offer any income-based discount or hardship pricing? A small number of telehealth platforms have introduced sliding-scale consultation fees for patients below 200% of the federal poverty level, though these programs are not widely advertised.

Safety and Regulatory Considerations That Affect Cost

The FDA's evolving stance on compounded peptides directly affects both availability and pricing of AOD-9604. In January 2024, the FDA began enforcing restrictions on certain peptides that had been available through compounding, citing safety concerns and lack of adequate clinical data [3]. While AOD-9604 was not among the first peptides restricted, the regulatory environment remains in flux.

The Phase IIb trial conducted by Metabolic Pharmaceuticals enrolled 300 obese adults (BMI 35 to 45) and randomized them to oral AOD-9604 at doses of 1 mg, 5 mg, or 25 mg daily versus placebo for 24 weeks [6]. The trial did not demonstrate statistically significant weight loss at any dose. Mean placebo-subtracted weight loss was approximately 1.1 kg in the highest-dose group. This underwhelming efficacy result is the primary reason no company has pursued further development.

Preclinical data in animal models showed more promising results. A 2000 study published in Obesity Research demonstrated that AOD-9604 reduced body fat in obese Zucker rats without affecting IGF-1 levels or insulin sensitivity [1]. The disconnect between animal and human data is typical for early-stage peptide therapeutics. Patients should understand that the evidence supporting AOD-9604 for fat loss is limited to preclinical studies and one failed Phase IIb trial, which is a meaningful consideration when deciding whether to spend $120 to $250 per month out of pocket.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity does not mention AOD-9604 among recommended therapies [13]. The guideline lists semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) as first-line pharmacotherapies for obesity, both of which demonstrated over 15% mean total body weight loss in Phase III trials. Patients considering AOD-9604 for weight management should discuss these FDA-approved alternatives with their prescriber, particularly since both semaglutide and tirzepatide have manufacturer-sponsored patient assistance programs for eligible low-income patients [5].

Practical Checklist: Reducing Your AOD-9604 Costs

Patients prescribed AOD-9604 who need to minimize monthly spending should follow a specific sequence. First, confirm the prescription is medically appropriate by discussing the evidence base and FDA-approved alternatives with the prescribing clinician. Second, obtain quotes from at least three compounding pharmacies, requesting cost per milligram and total monthly cost at the prescribed dose. Third, ask each pharmacy about multi-vial discounts, loyalty pricing, or hardship programs. Fourth, check whether the state of residence operates a pharmaceutical assistance program that covers compounded medications. Fifth, if using a telehealth platform, verify whether income-based pricing is available and whether the subscription can be paused without penalty.

Patients with HSA or FSA funds should obtain a letter of medical necessity before submitting reimbursement claims. Those near an FQHC should consider routing their consultation visits through the sliding-fee-scale clinic to reduce prescriber costs even if the peptide itself must be purchased separately. Every dollar saved on the consultation is a dollar available for the medication.

The peptide compounding market is price-sensitive and competitive. Pharmacies that quoted $130 per vial six months ago may now charge $90 due to increased competition from telehealth-affiliated dispensaries. Requoting every 60 to 90 days is a reasonable practice for patients on long-term therapy.